Wall Street’s Top Analysts Upgrades, Downgrades & Initiations

Wall Street’s Top Analysts Upgrades, Downgrades & Initiations

$AMZN, $AMED, $ALV, $CVS, $ELOX

Daily HeffX-LTN reviews Wall Street analysts research reports to find new investing and trading ideas for our readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of Wall Street’s Top analysts outlook for Key issues for Thursday, as follows:

Amazon.com (NASDAQ:AMZN) analysts reiterated a Buy and the price target was raised to 1,900 from 1,750 at Argus. The independent research firm sees the fresh PillPack acquisition rattling drug stores and it raised its EPS estimate to 19.80 from 16.01 for Y 2019 and in Y 2018 to 12.93 from 12.63.

Amedisys Inc. (NASDAQ:AMED) was raised to Buy from Neutral with a 97 price objective at Merrill Lynch.

Autoliv Inc. (NYSE:ALV) was raised to Neutral from Sell with a 107 price target  at UBS.

CVS Health Corp. (NYSE:CVS) was maintained as Overweight but the price target was cut to 80 from 88 at Morgan Stanley.

Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) was started with a Buy rating and assigned a 31 price target at Citigroup. The 52-wk trading range is 3.60 – 24.60, and the consensus target price is 23.33.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH